共 314 条
- [1] Katz R(2004)Biomarkers and surrogate markers: an FDA perspective NeuroRx 1 189-195
- [2] Hesselstrand R(2008)COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker Ann Rheum Dis 67 1242-1248
- [3] Kassner A(2010)Osteopontin in the development of systemic sclerosis–relation to disease activity and organ manifestation Rheumatology (Oxford) 49 1989-1991
- [4] Heinegard D(2002)Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation J Rheumatol 29 2565-2570
- [5] Saxne T(2010)A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis Arthritis Rheum 62 580-588
- [6] Lorenzen JM(2005)Elevated matrix metalloproteinase-9 in patients with systemic sclerosis Arthritis Res Ther 7 R71-R79
- [7] Kramer R(1994)Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis Arch Dermatol Res 286 77-80
- [8] Meier M(1998)Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? Br J Dermatol 139 1020-1025
- [9] Werfel T(1988)Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites J Rheumatol 15 460-467
- [10] Wichmann K(2005)Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis Clin Exp Rheumatol 23 165-172